Background Migraine affects 1.1 billion people globally and is the second leading cause of
disability worldwide. In clinical trials, treatment efficacy is evaluated by comparing the …

Background Single-arm trial (SAT) data is increasingly reviewed for drug approvals by
regulators and Health Technology Assessment (HTA) bodies. Supplementary data in the …

Population‐adjusted indirect comparison (PAIC) is an increasingly used technique for
estimating the comparative effectiveness of different treatments for the health technology …

In evidence synthesis, effect modifiers are typically described as variables that induce
treatment effect heterogeneity at the individual level, through treatment‐covariate …

Background Anchored covariate-adjusted indirect comparisons inform reimbursement
decisions where there are no head-to-head trials between the treatments of interest, there is …

Venetoclax is a standard treatment for patients with chronic lymphocytic leukemia (CLL)
following covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy, despite relatively limited …

Backgound Lenalidomide‐based regimens are commonly used for early relapse in patients
with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of …

Population‐adjusted indirect comparisons, developed in the 2010s, enable comparisons
between two treatments in different studies by balancing patient characteristics in the case …

Introduction Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disease
characterized by a loss of motor neurons and progressive muscle weakness. Children with …

Introduction: Health technology assessment (HTA) agencies express a clear preference for
randomized controlled trials when assessing the comparative efficacy of two or more …